eBRAM Partners with Agency for Volunteer Service to Launch ‘Pro-Bono Online Mediation Scheme for Water Seepage Disputes’

HONG KONG,Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - In order to resolve conflicts and disputes between property owners and occupants in Hong Kong caused by water seepage issues, eBRAM International Online Dispute Resolution Centre (“eBRAM”), an independent non-profit arbitration and mediation organisation, today joined hands with the Agency for Volunteer Service to officially launch the Pro-bono Online Mediation Scheme for Water Seepage Disputes (“Scheme”). The Scheme is free of charge and aims to foster a harmonious community by providing the public with efficient and economical online mediation services to help resolve water seepage disputes in the community.The Scheme has received strong support from the “Joint Office” set up by the Food and Environmental Hygiene Department and the Buildings Department. When water seepage issues arise, both parties involved can agree to conduct mediation at any stage. The parties can do so by submitting a request through eBRAM’s platform under the Scheme. The platform will then arrange for independent and neutral volunteer mediators to mediate the parties’ dispute. The Scheme aims to enable parties to resolve disputes in the simplest, most cost-effective, and time-efficient manner.Actively Assumes Social Responsibility and Alleviates the Concerns and Difficulties of the CitizensThe issue of building leakage or water seepage is a common source of dispute in the Hong Kong community, and multi-faceted issue encompasses cost split and responsibility for carrying out repairs . This issue has been troubling property owners and occupants in Hong Kong, as it is complicated and involves multiple parties’ responsibilities. Traditional legal proceedings are time-consuming and expensive, making it difficult to resolve these issues in a short period of time, which often causes great suffering to the residents involved.In view of this, as a leading non-profit arbitration and mediation organisation in Hong Kong, eBRAM actively uses innovative approaches to address social livelihood issues. Launched in cooperation with the Agency for Volunteer Service and supported by the Food and Environmental Hygiene Department and the Buildings Department, this free online mediation service fills a gap in legal services and provides an efficient, economical and convenient solution for members of the public who are in need.Efficiently Resolves Water Seepage Disputes, Highlights Advantages of Online MediationeBRAM’s mediation rules and online dispute resolution platform have overcome the time and space limitations of traditional mediation, allowing parties to participate in mediation process anytime and anywhere. Compared with cumbersome litigation procedures, online mediation is fast and efficient, and lowers the threshold for resolving disputes so that both parties do not have to go through lengthy legal proceedings and pay expensive litigation fees. This flexible service model meets the needs of the busy public living in modern cities to build a harmonious community.In addition, mediation is led by the parties involved, who have more control over the outcome. Both parties can work together to agree on a solution, rather than leaving the decision-making process entirely to the court. At the same time, mediation emphasizes fairness and understanding, which aims to reduce tensions between the parties, avoids escalation of conflicts, and protects their neighbourhood relations. As a third party, professional mediators maintain a neutral stance and assist the parties in discussing feasible solutions that give them peace of mind.Innovative LawTech to Help Build a Harmonious FutureDr Thomas So, JP, Chairman of eBRAM, said, "We are committed to serving our society, promoting sustainable development, and giving back to the community by leveraging innovative technologies and applying our expertise. By collaborating with the Agency for Volunteer Service and with the support of the Food and Environmental Hygiene Department and the Buildings Department, the launch of the free ‘Pro-bono Online Mediation Scheme for Water Seepage Disputes’ has not only helped solve the public’s livelihood issues, but also provided new ideas for building a harmonious and inclusive social environment. Looking ahead, we will continue to work closely with the government and other organisations to provide high-quality and efficient dispute resolution services to more members of the public."Ms. Melissa Pang, BBS, MH, JP, Chairman of the Agency for Volunteer Service, said, "We have always been attentive to the needs of the members of the public and are committed to playing a pivotal role in collaborating with various sectors of society to address livelihood issues. By having dedicated professional mediators who are passionate about serving society as volunteer workers, we provide free mediation services to relevant owners and occupants through eBRAM’s online platform, believing that we can play a crucial role in resolving building leakage disputes within the community. We look forward to promoting community harmony through this innovative initiative, ensuring that members of the public can live and work in peace."According to the figures released by the Joint Office, over the past five years, there have been an average of over 40,000 complaints per year on water seepage issues. The number of cases in which the source of water seepage was identified and relevant investigations completed averaged around 5,800 cases per year, accounting for approximately 14.5% of the total number of complaints. As at September 2023, the number of cases under investigation was around 10,000. Between 2020 and 2022, investigation on approximately 30% of the cases could not be completed and complainants were not informed of the investigation results within 90 working days. The “Pro-bono Online Mediation Scheme for Water Seepage Disputes” initiated by eBRAM and the Agency for Volunteer Service is set to effectively reduce the time required to handle water seepage cases, increase efficiency in addressing the public’s livelihood issues, and play a more active role in promoting harmony in the community and reducing social conflicts.“Pro-bono Online Mediation Scheme for Water Seepage Disputes” Webpage:https://ebram.org/Water_Seepage_POM_Scheme/?language=en Copyright 2024 ACN Newswire via SeaPRwire.com.
More

從亞洲到全球 順豐控股開啟新一輪價值躍升

香港, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) - 在中國物流行業,順豐控股(6936.HK)是當之無愧的領跑者。公司從時效快遞起家,通過直營模式,確立在中高端時效快遞領域的領先地位,並率先進行了資源全球化佈局,進行業務的多元化佈局,逐步發展成為業務覆蓋物流行業各核心細分領域的綜合物流服務龍頭。2023年,順豐控股實現營收人民幣2,584億元,在全球綜合物流服務提供商中僅次於聯合包裹服務公司(UPS)、敦豪(DHL)和聯邦快遞(FedEx)。站在行業變革的關鍵時刻,順豐控股將目光從中國及亞洲擴展至全球市場。11月27日,公司於聯交所上市,以期藉助這一契機,加速全球化戰略的推進,助力公司在高質量發展的基礎上,實現新一輪的躍升。新老業務協同發展 新業務陸續迎來盈利增長順豐控股全方位佈局物流業務,其業務版圖覆蓋時效快遞、經濟快遞、快運、冷運物流、同城即時配送以及供應鏈和國際服務領域,在各業務領域均建立領先競爭力。其中,時效快遞作為順豐控股基本盤,2023年市場份額高達63.9%。過往期間,公司持續夯實時效服務競爭力,同時不斷拓展新興產業客群和新業務場景,營收穩步增長,2024年上半年該項業務營收同比增加5.6%。同時,順豐控股新業務也陸續收獲了耕耘果實。快運業務方面,順豐控股在客戶便利性、時效性、准時性等方面持續打造競爭優勢,大件業務於2022年首次實現轉盈,2023年盈利進一步擴大。同城即時配送分部方面,公司通過業務結構優化、精細化管理及科技驅動提升經營能力,2023年首次實現整體盈利,2024年上半年淨利潤擴大至0.62億元。與此同時,順豐控股還通過采取多项降本增效举措,包括推進多網融通,整合天網、地網的物流資源與信息網、優化業務結構以及精益管理等,提升運營效率,促進降本增效。2024年上半年,公司毛利率達到13.6%,較去年同期提升0.3個百分點。可以預見,隨著新業務規模的持續增長以及降本增效效應的加持,公司的盈利水平有望進一步提升。行業景氣度有望延續 國際化拓展高質量成長可期從行業的角度看,物流行業作為經濟的"晴雨表",依然蘊含著巨大的市場機遇。預計2028年,全球物流支出總額將達到13.8萬億美元,2023年至2028年複合年增長率為4.4%。其中,亞洲作為全球規模最大及增長最快的物流市場,且是集中度最低的地區之一,擁有可觀的增長前景,預計2023年至2028年間複合年增長率為5.5%。順豐控股多年經營,於中國市場打下堅實發展根基,品牌形象深入人心。隨後公司深耕中國及亞洲市場,不斷孵化新產品、投資基礎設施,市場份額持續擴大,為未來全球拓展做好準備。未來,順豐控股計劃鞏固其在中國的市場領導地位,同時擴展在亞洲和全球的影響力。在亞洲市場,依託已經建立的龐大的本地物流網絡、廣泛的互通互聯、強大的品牌知名度及團隊,順豐控股有能力複製中國成功經驗,擴展高增長市場。在亞洲以外,利用公司品牌、成本優勢以及綜合物流能力,順豐控股能夠為全球客戶提供具有價格競爭力的一站式解決方案,佔據更大的市場份額。隨著登陸港股資本市場,打造國際化資本運作平台,順豐控股的綜合競爭力也將在資本的助力下得到加強,為國際化戰略加速推進提供有力支持。疊加持續提升其經營能力,公司高質量可持續增長可期。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More

一邦攜手義務工作發展局推出「滲漏糾紛義務網上調解服務」

香港, 2024年12月3日 - (亞太商訊 via SeaPRwire.com) - 為解決本港業主及住戶因樓宇滲水問題所引發的矛盾和糾紛,獨立非營利仲裁調解機構一邦國際網上仲調中心(「一邦」)攜手義務工作發展局,於今天正式推出費用全免的「滲漏糾紛義務網上調解服務」,致力為市民提供高效、經濟的網上調解服務,協助解決社區滲水糾紛,促進鄰里和諧及實現社區共融。該服務計劃獲得由食物環境衞生署及屋宇署組成的「聯合辦事處」(俗稱「滲水辦」)的大力支持,當滲水問題發生後,有關雙方可以在任何階段隨時同意進行調解, 屆時市民可通過由一邦的網站提交聯絡資料及調解申請書,並透過平台安排獨立及中立的義務調解員進行調解。此免費調解服務務求雙方以最簡單、符合效益及省時的方法解決爭議。積極承擔社會責任,為市民解憂緩困樓宇漏水或滲水問題是香港社區中常見的糾紛來源,當中涉及費用分攤、維修責任等不同層面的問題。此民生問題纏擾大量香港業主及住戶、複雜且涉及多方責任。傳統的法律程序既耗時又昂貴,難以在短時間内解決問題,涉事居民均苦不堪言。有見及此,一邦作為香港領先的非營利仲裁調解機構,積極以創新思維解決社會民生議題。本次與義務工作發展局合作、得到食物環境衞生署及屋宇署支持推出的免費義務網上調解服務,彌補了這一項法律服務空白,為有需要的市民提供了一個高效、經濟、便捷的解決途徑。高效解決滲水糾紛,網上調解優勢顯著一邦的調解規則及網上爭議解決平台突破了傳統調解的時間和空間限制,讓當事人可以隨時隨地參與調解過程,相比繁瑣的訴訟程序,網上調解快捷高效,雙方無需經歷冗長的法律程序及昂貴的訴訟費用,降低解決爭議的門檻。這種靈活的服務模式符合現代都市生活繁忙的市民的需求、構建和諧社區。此外,調解過程由當事人主導,當事人擁有對結果的更多控制權,雙方能共同商定解決方案,而非將決策權完全交予法庭。同時,調解強調公平和理解,能緩解雙方的緊張情緒,避免衝突升級,並在一定程度上保護雙方的鄰里關係。而專業調解員作為第三方,秉持中立態度,協助雙方探討可行的解決方案,讓各方安心。創新法律科技,助力構建和諧未來一邦主席蘇紹聰博士表示:「我們一直以服務社會、推動可持續發展為己任,運用創新科技和專業知識回饋社會。此次能夠與義務工作發展局合作,得到食物環境衞生署及屋宇署支持,推出免費的『滲漏糾紛義務網上調解服務』,不僅解決民生問題,更為建設和諧共融的社會環境提供了新思路。未來,一邦將繼續與政府及其他機構緊密合作,為更多市民提供優質、高效的爭議解決服務。」義務工作發展局主席彭韻僖女士表示:「我們一直關注市民需求,並致力承擔樞紐角色,與社會各界建立夥伴關係以解決民生問題。我們招募配對有心服務社會的專業調解員義工,透過一邦的網上法律平台,向相關業主或租戶提供免費的調解服務,相信能在解決樓宇滲漏爭議發揮關鍵作用。我們期待透過是次創新措施,促進社區和諧,使市民都能安居樂業。」根據「滲水辦」的數字顯示,過去5年平均每年接獲逾4萬宗涉及單位滲漏的投訴,成功找出滲水源頭並完成調查的個案數目,平均每年約有5,800宗,佔整體投訴約14.5%。截至2023年9月,仍在進行調查的個案數目約為1萬宗,而在2020至2022年間約有30%的個案未能於90個工作天內完成調查並告知舉報人調查結果。一邦攜手義務工作發展局推動的「滲漏糾紛義務網上調解服務」,相信能夠有效縮減處理滲水個案的時間,提高效率以解決市民的生活問題,並在促進社區和諧、減少社會矛盾方面發揮更大作用。「滲漏糾紛義務網上調解服務」網頁:https://ebram.org/Water_Seepage_POM_Scheme/?language=tc Copyright 2024 亞太商訊 via SeaPRwire.com.
More
#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions ACN Newswire

#CTS24 Concluded Last Week, Advancing Net-Zero Goals and Sustainable Solutions

London, UK, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - The 3rd edition of the London Climate Technology Show concluded last week, paving a vital roadmap towards fully decarbonising our planet through sustainable technologies. The event brought together policymakers, eco-technology leaders, industry professionals, and innovators, all unified in their call for an immediate shift to sustainable and green solutions to secure a better future for the planet.The two-day event opened on 27th November with an inspiring keynote by Felicity Burch, Executive Director of the Responsible Technology Adoption Unit at the Department for Science, Innovation, and Technology (DSIT), who spoke about AI Innovation in Clean Energy and the DSIT's Manchester Prize. Following her, Ing. Abigail Cutajar, CEO of the Climate Action Authority, talked about Pioneering the Surge Towards Climate and Energy Transitions.The conference unfolded over two dynamic days, featuring a packed agenda of insightful presentations and engaging panel discussions. It delved into actionable strategies for decarbonisation, advancements in AgriTech, the evolving carbon market, eco-funds, energy, CCS, built environment and other groundbreaking innovations in climate technology.Notable discussions highlighted the need for farmers to balance carbon stewardship with food production over the next few decades, the importance of consistent government policies to enable businesses to plan and innovate effectively, and the urgency of addressing digital and engineering skill shortages to ensure a successful green energy transition. Industry experts also called for common sustainability metrics to measure corporate efforts fairly, emphasized the value of collaboration over competition to accelerate the green transition, and underscored the need for farmers to access landscape-level data to enhance biodiversity.The exhibition hall featured groundbreaking innovations and solutions in sustainability and climate technology, including carbon capture and storage (CCS) from companies like CGI and Terra CO2 Technology, carbon management and accounting solutions by Greenly and Gaia Carbon Accounting, and emerging climate technologies from innovators such as Nabla Flow and Luna 9. Other exhibitors showcased AI-driven solutions, sustainable energy systems, and innovative carbon reduction technologies, presenting a comprehensive snapshot of the future of climate tech.#CTS24 also hosted interactive side events, including startup acceleration programs and hands-on workshops, providing participants with opportunities for learning, networking, and collaboration. These sessions empowered attendees to adopt transformative technologies and take decisive climate action.Attendee ExperiencesThe event received overwhelming positive feedback:Mark Haley, Co-founder of Cero3, shared, "We’re so proud to have unveiled our sustainable travel planner. The feedback and interest exceeded our expectations."Satyajit Mohanan, Projects and Business Development Coordinator at Cambridge Cleantech, remarked, "It was a pleasure to be part of this event. I met amazing people and look forward to the next edition."Dennis Chacko, Senior Sales Manager at the British Board of Agreement, shared his excitement over a unique sustainable pen: "Once used, you can plant it to grow something new—a powerful reminder of how everyday items can contribute to a greener future."As this successful edition concludes, the organisers are already planning for a bigger, more impactful 4th Edition, with expanded content and greater opportunities to drive meaningful change toward a sustainable future.For further information, please reach out to us at press@valiantandcompany.com. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利 ACN Newswire

康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利

深圳, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司(以下簡稱「康哲藥業」)欣然宣佈,於2024年12月2日,通過其全資附屬公司與杭州新元素藥業有限公司(以下稱「新元素藥業」,曾用名「江蘇新元素醫藥科技有限公司」)就治療痛風及高尿酸血症的1類新藥ABP-671(「產品」)簽訂獨家商業化協議(「協議」)。根據協議,康哲藥業獲得產品在中國大陸、香港特別行政區及澳門特別行政區的獨家商業化權利。合作期限開始於協議生效之日,自產品首次在中國大陸獲批上市起擁有十年的授權期限(「授權期限」)。授權期限屆滿後,根據協議約定的特定條件,授權期限可自動續期十年。ABP-671是用於治療痛風及高尿酸血症的化藥1類創新藥,目前正分別在中國和境外開展關於痛風的2b/3期臨床試驗,產品通過抑制尿酸鹽轉運蛋白1(URAT1),降低腎臟對尿酸的重吸收。在已經完成的兩項2期臨床試驗結果顯示,ABP-671多個劑量組(1mg至12mg)表現出良好的藥效和安全性。該產品2mg每天單次給藥,其藥效可能相當於或優於苯溴馬隆和非布司他最高劑量80mg的藥效。尿酸下降可維持全天候24小時,沒有出現嚴重的安全性問題。產品有望為痛風及高尿酸血症患者帶來療效更優、安全性更高的治療選擇[1]。與ABP-671相關的化合物和用途方面的多個專利已在中國獲得授權。高尿酸血症是指成人在正常嘌呤飲食情況下,非同日2次空腹血尿酸水平超過420μmol/L (7.0mg/dL)。高尿酸血症患者出現尿酸鹽晶體沉積,導致痛風性關節炎,稱為痛風。高尿酸血症及痛風可引起關節軟骨、骨質、腎臟以及血管壁等急慢性炎症損傷,導致心、腦、腎等多器官損害。《2021中國高尿酸及痛風趨勢白皮書》數據顯示,我國高尿酸血症的總體的患病率為13.3%,高尿酸血症患病人數約1.77億人,痛風總體發病率為1.1%,患病人數約為1,466萬。據弗若斯特沙利文分析,未來中國高尿酸血症和痛風患病人數會持續增加,將在2030年分別達到2.4億人、5,220萬人。目前我國臨床上常用的降尿酸藥物主要包括抑制尿酸合成和促進尿酸排泄兩類,由於已上市降尿酸藥物在療效和安全性上仍存在一定的局限性,如導致腎衰竭、心臟猝死或嚴重肝臟毒性等。中國痛風及高尿酸血症患者對高效安全的降尿酸藥物仍然有迫切的需求。ABP-671是當前痛風及高尿酸血症治療中潛在療效優、安全性好的產品。通過本次合作引進,填補了康哲藥業痛風治療產品的空白。痛風及高尿酸血症既屬於風濕疾病又屬於慢性代謝性疾病,與康哲藥業心腦血管/消化業務的戰略佈局,以及在售品種的網絡資源高度契合。ABP-671如未來獲批上市,在風濕免疫科可與在售產品美泰彤(甲氨蝶呤注射液),在內分泌科和骨科可與益蓋寧(依降鈣素注射液)在專家網絡與市場資源方面協同。基於未滿足的臨床需求和產品預期扎實的臨床數據,期待ABP-671的臨床開發工作順利推進,使相關適應症患者儘快從創新療法中獲益。關於新元素藥業新元素藥業創辦於2012年3月,專注於代謝和炎症領域疾病中具有全球商業價值和全球競爭力的創新藥的研發。新元素藥業主要核心團隊人員來自美國,具有廣泛的創新藥物的研發經驗,過去幾年新元素藥業取得了顯著的發展成果。其核心產品ABP-671正處於後期臨床研發階段,用於治療慢性痛風;另一個小分子創新藥物ABP-745用於抗炎自免領域適應症,已完成1期臨床,表現出良好的PK和安全性,即將進入2期臨床。有關新元素藥業及其產品的更多信息,請訪問其官方網站:https://www.atombp.com/。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平臺型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化業務競爭力,並將皮膚醫美、眼科業務獨立運營,培育專科小領域的大龍頭,提升專科規模效率。同時業務版圖拓展至東南亞市場,著力成為全球藥企進軍東南亞市場的「橋頭堡」,助力康哲藥業高質量持續健康發展。參考文獻:1.產品2期臨床試驗結果已發佈,詳情如下:https://www.atombp.com/2023/03/01/atom-bioscience-announces-positive-results-of-phase-2a-china-clinical-trial-of-its-urat1-inhibitor-for-chronic-gout/康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
15 Companies Pitch Their Capabilities at GA-ASI’s Blue Magic Netherlands ACN Newswire

15 Companies Pitch Their Capabilities at GA-ASI’s Blue Magic Netherlands

SAN DIEGO, CA, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - On November 19, 2024, General Atomics Aeronautical Systems, Inc. (GA-ASI) hosted its first Blue Magic Netherlands (BMN) event in Eindhoven, the Netherlands. Approximately 200 people attended the event that provided Dutch businesses with an opportunity to present their capabilities to GA-ASI and other companies interested in possible collaborations. GA-ASI was joined for the event by the Netherlands Ministry of Economic Affairs, the Netherlands Ministry of Defence, Lockheed Martin Ventures, Brainport Development, Brabant Development Agency (BOM), the Netherlands Industries for Defence & Security (NIDV), and SpaceNED.At this event, GA-ASI and its partners heard first-hand from Dutch companies about the important capabilities they are developing. The process started in July when GA-ASI put out an open invitation to Dutch businesses to apply for the opportunity to present innovative technologies at the November 19 event. Key areas of focus included Artificial Intelligence/Machine Learning, Autonomy, Advanced Materials, Sensors, Advanced Manufacturing, and Space. Close to 50 companies applied and after reviewing the applications, 15 businesses were selected to pitch their capabilities to an audience that included lightweight lattice structures, gas detection technologies, advanced battery and photonics applications, and several innovative unmanned system and AI applications, among many others."This event is where the rubber meets the road," said Brad Lunn, Managing Director-Strategic Finance at GA-ASI. "In addition to attracting many companies, we increased the areas of expertise and depth of knowledge from the presenting companies in order to provide research, development, and breakthrough innovations to support current and future missions by GA-ASI aircraft. We also wanted to give the companies an opportunity to pitch in front of other potential customers, partners, and investors."The first Blue Magic event held by GA-ASI was in 2019 in Belgium, with subsequent events held in 2020, 2021, and 2023. GA-ASI is delivering eight MQ-9A Remotely Piloted Aircraft to the Royal Netherlands Air Force (RNLAF).GA-ASI expects to announce technology partnerships stemming from the BMN event and intends to hold this event on an annual basis in the Netherlands.About GA-ASIGeneral Atomics Aeronautical Systems, Inc. (GA-ASI), an affiliate of General Atomics, is a leading designer and manufacturer of proven, reliable remotely piloted aircraft (RPA) systems, radars, and electro-optic and related mission systems, including the Predator® RPA series and the Lynx® Multi-mode Radar. With more than eight million flight hours, GA-ASI provides long-endurance, mission-capable aircraft with integrated sensor and data link systems required to deliver persistent flight that enables situational awareness and rapid strike. The company also produces a variety of ground control stations and sensor control/image analysis software, offers pilot training and support services, and develops meta-material antennas. For more information, visit www.ga-asi.com.Avenger, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are registered trademarks of General Atomics Aeronautical Systems, Inc.Contact InformationGA-ASI Media Relationsasi-mediarelations@ga-asi.comSource: General Atomics Aeronautical Systems, Inc. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance’s First Promotional Seminar and Non-Deal Roadshow Successfully Held ACN Newswire

Advancing the Belt and Road Initiative: The Kyrgyz Republic Ministry of Finance’s First Promotional Seminar and Non-Deal Roadshow Successfully Held

HONG KONG, Dec 3, 2024 - (ACN Newswire via SeaPRwire.com) - December 2, 2024, In the context of the Belt and Road Initiative, the first Belt and Road Golden Route Series Financial Promotion Event——the Kyrgyz Republic Ministry of Finance's promotional seminar and non-deal roadshow was successfully held today in Hong Kong. The event was jointly hosted by TF International Securities Group Limited ("TF International") and China CITIC Bank International Limited ("China CITIC Bank International"), attracting numerous international investors and financial industry leaders.The Kyrgyz Republic, as one of the earliest countries to support and engage in the Belt and Road Initiative, has seen increasingly close economic and trade relations with China. Recently, TF International signed a memorandum of understanding with the Kyrgyz Republic Ministry of Finance, becoming the first Hong Kong-based Chinese securities firm to establish an official partnership with the Kyrgyz Republic Ministry of Finance. The two parties work together to promote the RMB internationalization, support the real economy, facilitate high-quality development, and reinforce Hong Kong’s position as an international financial center. The event featured distinguished guests, including Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of Kyrgyz Republic, Mr. Abdybapov Abdanbek Abdybapovich, Head of the Government Borrowing Department of Kyrgyz Republic, Mr. CHAN Ho Lim, Joseph, JP, Under Secretary for Financial Services and the Treasury of Hong Kong S.A.R., and Mr. ZOU Chuan, CEO of TF International, as well as Mr. Andy Siow, Senior Coverage Banker, DCM, at China CITIC Bank International. They shared insights into Kyrgyzstan’s development opportunities and investment prospects in the international financial market, discussing investment opportunities and key focus areas for mutually beneficial cooperation. In his opening speech, Mr. CHAN Ho Lim, Under Secretary for Financial Services and the Treasury of Hong Kong, remarked, "Hong Kong has firmly established itself as Asia’s leading international financial centre. Our core strengths include free flow of capital and information, a robust common law system, and a simple and low tax regime, and Hong Kong enjoys preferential access to Mainland China. All these position Hong Kong as the super-connector between China and international markets, which plays a key role in promoting RMB internationalization and advancing the Belt and Road Initiative. The Kyrgyz Republic is an important partner under the Belt and Road Initiative and is certainly Hong Kong’s important trading partner in Central Asia.” He also stated that, “I would like to express my gratitude to the Kyrgyz Republic Ministry of Finance and TF International and appreciate your commitment to fostering stronger ties between Central Asia and Hong Kong. We look forward to exploring potential future collaborations with the Kyrgyz Republic that will benefit our respective markets and promote partnerships among Belt and Road nations.” As of September 1, 2024, Renminbi (RMB) has been included in the list of official daily exchange rates published by Kyrgyzstan, alongside the US dollar, euro, Russian ruble, and Kazakh tenge. This move further strengthens economic and financial cooperation between the two countries. Mr. Amanbaev Umutzhan Mominovich, Deputy Minister of Finance of the Kyrgyz Republic, stated, "The inclusion of the RMB in the list of official daily exchange rates in Kyrgyzstan marks a new stage in the economic cooperation between the two countries. This not only provides greater convenience for international investors but also empowers the development of Kyrgyzstan's financial market. Through this promotional event, we hope to connect with more international investment institutions and jointly promote the sustainable development of the regional economy." Hong Kong, as the international financial center and the central city of the Guangdong-Hong Kong-Macao Greater Bay Area, plays an important bridging role in the Belt and Road Initiative, leveraging its diverse financing channels and close alignment with national strategies. Mr. ZOU Chuan, CEO of TF International, stated, "The Belt and Road Initiative offers significant opportunities for economic integration and development, enhancing trade across Asia, Europe, the Middle East, and beyond. As a gateway between China and the world, Hong Kong is a key hub for the internationalization of the Renminbi, facilitating its use in trade and investment, and supporting effective currency risk management for BRI projects. With ongoing economic expansion and the internationalization of the Renminbi, Hong Kong is well-positioned to emerge as the premier financing hub. As we explore upcoming opportunities, I encourage you to envision the transformative impact these initiatives can have on the Kyrgyz Republic’s development agenda and the broader economic landscape of Central Asia. Together, we can unlock new avenues for growth and collaboration." From December 3 to 6, 2024, TF International, in collaboration with China CITIC Bank International will join forces with the Kyrgyz Republic Ministry of Finance in hosting a series of non-deal roadshows in Shanghai and Beijing, further strengthening ties with the Chinese financial market. The success of today’s promotional seminar and non-deal roadshow in Hong Kong marks a new milestone in the economic cooperation between the two countries and injects fresh momentum into the high-quality development of the Belt and Road Initiative. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行 ACN Newswire

共建一帶一路:吉爾吉斯斯坦國家財政部首場推介會暨非交易性路演成功舉行

香港, 2024年12月3日 - (亞太商訊 via SeaPRwire.com) - 2024年12月2日,在「一帶一路」倡議的背景下,由天風國際證券集團有限公司(以下簡稱「天風國際」)與中信銀行(國際)有限公司(以下簡稱「信銀國際」)聯合主辦的首場「一帶一路」黃金線系列金融推介會——吉爾吉斯斯坦國家財政部推介會暨非交易性路演於今日在香港圓滿舉行。本次活動吸引了眾多國際投資機構及金融行業領袖出席。吉爾吉斯斯坦作為最早支持和參與「一帶一路」倡議的國家之一,近年來與中國的經貿合作關係日益密切。近期,天風國際與吉爾吉斯斯坦國家財政部簽訂合作備忘錄,成為首家與吉爾吉斯斯坦國家財政部建立合作關係的駐港中資券商。雙方將就共同推動人民幣國際化願景,服務實體經濟,助力高質量發展,為維持並進一步鞏固香港作為國際金融中心的地位,展開更廣泛的合作。本次活動邀請了多位重量級嘉賓,包括吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生、政府借貸部主任Abdybapov Abdanbek Abdybapovich先生、香港特別行政區政府財經事務及庫務局副局長陳浩濂太平紳士,以及天風國際行政總裁鄒傳先生和信銀國際高級董事、債券資本市場、財資及環球市場Andy Siow先生。會上,嘉賓們分享了吉爾吉斯斯坦在參與國際金融市場的發展機遇與其投資前景,共同探討了雙方互利共贏的合作著力點。陳浩濂副局長在致辭中表示:「香港作為全球主要國際金融中心,具備資本與信息的自由流動、穩健的普通法制度以及單一稅制等核心優勢,同時香港與中國內地市場聯繫緊密,在促進人民幣國際化和推動『一帶一路』倡議中發揮著關鍵作用。而吉爾吉斯斯坦作為『一帶一路』倡議下的重要合作夥伴,毫無疑問,也是香港在中亞地區的重要貿易夥伴。感謝天風國際的精心組織和吉爾吉斯斯坦代表團的到訪,今天我們齊聚一堂,探討如何進一步加强中亞與香港之間的經濟合作。我們期待未來與吉爾吉斯斯坦的合作將為兩國經濟增長注入新的動力,推動『一帶一路』國家之間的多層次合作,進一步促進區域經濟的可持續發展。」自2024年9月1日起,人民幣已正式列入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單,與美元、歐元、俄羅斯盧布和哈薩克斯坦堅戈一起,成為吉爾吉斯斯坦每日公佈匯率的貨幣,這一舉措進一步深化了兩國在經濟與金融領域的合作。吉爾吉斯斯坦國家財政部副部長Amanbaev Umutzhan Mominovich先生在會上表示:「人民幣成功納入吉爾吉斯斯坦官方每日公佈匯率的貨幣名單,標誌著兩國經濟合作進入了新的階段。這不僅為國際投資者提供了更多便利,也為吉爾吉斯斯坦的金融市場發展賦能。我們希望通過此次推介會,與更多國際投資機構建立聯繫,共同推動區域經濟的可持續發展。」香港作為國際金融中心,同時也是粵港澳大灣區的核心城市,憑藉多樣的融資渠道和與國家戰略的深度對接,在「一帶一路」倡議中發揮了重要的橋梁作用。作為此次活動的聯合主辦方之一,天風國際行政總裁鄒傳先生在致辭中提到:「『一帶一路』倡議為經濟一體化和發展提供了巨大機遇,推動亞歐、中東乃至更廣泛地區的貿易往來。香港作為中國市場聯通世界的重要窗口,同時也是人民幣國際化的關鍵樞紐,促進人民幣在貿易和投資中的使用,支持『一帶一路』項目的融資與匯率風險管理。隨著人民幣國際化的推進,香港正穩步成為全球領先的融資中心。在探索未來機遇的同時,期待今日的活動與市場洞察的深入分享,對吉爾吉斯斯坦發展進程以及中亞經濟帶來積極、深遠的影響。」後續,天風國際聯合信銀國際將陪同吉爾吉斯斯坦國家財政部於12月3日至6日期間,陸續在上海和北京繼續舉辦系列非交易性路演活動,進一步深化吉爾吉斯斯坦與中國金融市場的聯繫。此次香港推介會的成功舉辦標誌著兩國在經濟領域合作邁向新高度,為「一帶一路」倡議的高質量發展注入了新動能。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Edvantage Group Announces FY2024 Annual Results ACN Newswire

Edvantage Group Announces FY2024 Annual Results

Highlights (relevant audited data for the year ended 31 August 2024)- Revenue increased by 17% YoY to approximately RMB2,312 million;- Gross profit rose by 10% YoY to approximately RMB1,124 million;- Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million;- Number of student enrolments increased by 11% YoY to approximately 95,600;- Payment of a final dividend of HK10.0 cents per share;- Dividend payout ratio of 30% for the year.HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - Edvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) has announced its audited FY2024 Annual Results for the year ended 31 August 2024 (the “Reporting Period”). During the Reporting Period, the Group actively responded to national policies, vigorously promoted industry-education integration, deepened the connotations of international education, continued to introduce unique new featured majors that match market and industry demands and fully embraced artificial intelligence (“AI”), succeeding in raising education quality and brand presence, thereby achieving steady growth in performance year after year.During the Reporting Period, the Group’s revenue totaled approximately RMB2,312 million, representing an increase of 17% as compared to the corresponding period of the preceding year. The increase was mainly attributable to the continuous enhancement of the Group’s education brand effectiveness, which drove a rise in the number of student enrolments and higher average tuition fees recorded by the Group’s domestic schools. Profit for the period attributable to owners of the Company rose by 16% YoY to approximately RMB715 million. The number of students enrolled in the Group’s schools continued to expand yearly, reaching approximately 95,600, with a year-on-year growth of approximately 11%. The Board of Directors of the Group has recommended the payment of a final dividend of HK10.0 cents per share for the year ended 31 August 2024, which, along with an interim dividend of HK9.6 cents per share, equates to a total annual dividend of HK19.6 cents per share and a dividend payout ratio of 30% for the year.From left to right: Mr. Yan Kwok Ting Sunny, Director of Investment, Corporate Finance & Investor Relations Department;Mr. Liu Yuk Tung, ChiefFinancial Officer; Ms. Liu Yi Man, Executive Director and Chief Executive Officer;Ms. Liu Wenqi, Chief Operating Officer;Fully embracing AI and continuously promoting the industry-education integrationOver the past year, the Group witnessed the groundbreaking development of the new generation of artificial intelligence technology. As a vocational education provider, the Group has developed in step with times, fully embracing AI in teaching, management and application. At present, all of its schools are actively promoting AI, fostering its popularity, with AI-embedded courses launched in seven colleges. Subsequent efforts will be made to promote those programmes to cover all faculties and students of all schools under the Group. Meanwhile, the Group actively responded to national policies, continuously deepened industry-education integration, and fully promoted the construction of industrial colleges, cooperating with multiple enterprises renowned in their respective industries to establish artificial intelligence and big data, digital trade, digitalised accounting and business services, research and tourism, jewelry, human resources and other industrial colleges. Those industrial colleges are all set up according to the Ministry of Education requirements for building modern industrial colleges that align with the country’s key industry development strategies, in order to nurture high-quality application-minded talent that emerging industries urgently need. In addition, the Group also entered into school-enterprise cooperation with numerous enterprises to build off-campus practice bases, further promoting the in-depth integration of education chains and industrial chains.Expanding exchange and cooperation of international education and deepening the connotations of international educationThe Group responded to the national advocacy for the opening up of education, “introduction of foreign schools”, and “international expansion of domestic schools”, continuously promoted the internationalisation of vocational education and expanded the partnership network with global renowned universities. By providing high-quality international programs and practice opportunities to students, the Group aims to cultivate innovative talents with global vision, to further raise the international influence of China’s vocational education. During the Reporting Period, the schools under the Group established in-depth cooperation with 51 foreign high schools in the United States of America, the United Kingdom, Canada, Japan and Australia, joining hands to create diverse high-quality international programmes. Furthermore, the Group comprehensively launched international study tours, organising 65 student and teacher study tours to France, Singapore, Hong Kong, China, Macau, China and other regions for short-term studies, with over 4,000 teachers and students participating during the Reporting Period. Looking forward, the Group will press on with deepening integration of its schools - domestic and international, strive to build a diversified international education cooperation network, actively promote Chinese vocational education to go global and build an internationally renowned Chinese vocational education brand.Consistently increasing investment in education to build a high-quality education brandThe Group has always adhered to the motto of "Establishing school of the century, Nurturing talents of the nation". Firmly believing that increasing investment in education is an important path towards high-quality education, the Group further expanded the new campus of Guangzhou Huashang College and Guangzhou Huashang Vocational College during the Reporting Period, which includes student dormitories, library, sports centre, teaching buildings and laboratories, providing solid support for future student enrollment and sustainable development of the Group. At the same time, it has kept increasing investment in building a high-quality teaching staff, which has expanded after the Guangzhou Huashang College and Guangzhou Huashang Vocational College established their Guangdong Province Doctoral Workstation respectively. The Group has launched a series of training workshops for teachers to continuously enhance their professionalism and practical teaching abilities, encouraging them to practice what they have learned and help improve school education and teaching quality. By introducing mentors from industries, it works together with enterprises in nurturing professional “dual-qualified” teachers and “dual-skilled” industry mentors, continuing to optimize the combined structure of full-time and part-time faculty teams. The in-depth and precise investment made by the Group in various areas crucial to strengthening school management has brought bountiful results. Guangzhou Huashang College placed third in scientific research competitiveness among private undergraduate colleges in China and has been designated as a key research base for humanities and social sciences among regular higher education institutions in Guangdong Province. Guangzhou Huashang Vocational College has been named a national exemplary vocational college, while the Urban Vocational College of Sichuan ranked second in China and first in Sichuan among Shanghai Ranking's 2024 Best Chinese Private Higher Vocational Colleges. These honors are a strong testament to the Group’s high-quality educational achievements.Looking ahead, the Group will continue to nurture innovative talent, focusing on such areas as industry and education integration, internationalization, and AI to keep up with industry and social development needs, increase investment in education, and keep building a high-quality education brand. It is committed to nurturing highly-skilled interdisciplinary corporate leaders for the country and industries around the world, while continuously making positive contributions to the sustainable development of vocational education.About Edvantage Group Holdings LimitedEdvantage Group Holdings Limited (“Edvantage Group” or the “Group”, stock code: 0382.HK) is the largest private business higher education and vocational education group in the Greater Bay Area, and an early mover in education sector in pursuing international expansion, listed in Hong Kong Main Board on 16 July 2019. The total number of full-time student enrolments of the Group was approximately 96,000 as of 31 August 2024. Operated 9 private education institutions, namely, Guangzhou Huashang College (Applied Undergraduate), Guangzhou Huashang Vocational College (Higher Vocational Education) and Guangdong Huashang Technical School (Secondary Vocational Education) located in Guangdong Province, the PRC; Urban Vocational College of Sichuan (Higher Vocational Education) and Urban Technician College of Sichuan (Secondary Vocational Education) in Sichuan Province, the PRC; GBA Business School (GBABS) in Hong Kong, the PRC; Global Business College of Australia (GBCA) and Edvantage Institute Australia (EIA) in Australia; as well as Edvantage Institute (Singapore) (EIS) in the downtown of Singapore.While focusing on school operations, the Group also actively fulfil corporate social responsibility, extensively contributing to social welfare programmes including charity, poverty alleviation, education and revitalisation, in order to take the initiative in repaying society through action. Since its listing, the Group has made outstanding contributions in the field of ESG and has won the “Best ESG Innovation Award” from Zhitong Finance and the “Outstanding Enterprise for ESG Innovative Practice” from Gelonghui in 2024. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
The Hong Kong Institute of Directors Announces Winners ACN Newswire

The Hong Kong Institute of Directors Announces Winners

HONG KONG, Nov 29, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Institute of Directors ("HKIoD") announced the winners of its Award Series for Director Excellence (the "Awards") – comprising the long-established Directors of the Year Awards ("DYA") and the inaugural Climate Governance Awards ("CGA"), at its Annual Dinner yesterday at the Hong Kong Convention and Exhibition Centre. The event began with an opening speech by Dr Christopher To, Chairman of the HKIoD. Dr The Hon Moses Cheng Mo Chi, Non-official Member of the Executive Council of HKSARG, Mr Xu Wei Gang, Director General, Department of Economic Affairs, Liaison Office of the Central People's Government in HKSAR, Ms Salina Yan, JP, Permanent Secretary for Financial Services and the Treasury (Financial Services), and Dr Kelvin Wong, Chairman, Securities and Futures Commission ("SFC") and Chairman, Accounting and Financial Reporting Council ("AFRC") were invited as guests of honour. The response to the Awards submissions was overwhelmingly positive. After a lively discussion among the judges, this year's 19 winners, including directors and boards, were selected - all embodying the theme "Leading with Agility in an Era of Innovation". The awardees have demonstrated not only agility, but also the vision, courage and wisdom to lead against the backdrop of a demanding economic environment and prevailing geopolitical tensions. Moreover, they highlight the importance of having directors who can guide their companies in identifying the risks and opportunities associated with climate change, which are vital for ensuring the sustainability of the world and humanity.The Awardees of HKIoD Award Series* for Director Excellence 2024 are listed below:*Two series of Awards:- "DYA", acronym for "Directors Of The Year Awards"- "CGA", acronym for "Climate Governance Awards"In alphabetical order of names within categoryListed Companies CategoriesExecutive DirectorsDYAMr Chan Wai MingTown Ray Holdings LimitedCGAMs Clara Chan Yuen-shanLee Kee Holdings LimitedDYAMr Fu FanChina Pacific Insurance (Group) Co., LtdCGA Mr Li Wai LeungHengan Internationals Group Company LimitedMr Peter Wong Wai-YeeThe Hong Kong and China Gas Company LimitedDYA & CGAMr Yan Jianguo JPChina Overseas Land & Investment LimitedNon-Executive DirectorsDYA Dr Chung Shui Ming TimpsonChina Railway Group LimitedDr Tseng Shieng-chang CarterTCL Electronics Holdings LimitedProf Wang YijiangTCL Electronics Holdings LimitedBoardsDYA & CGAChina Resources Beer (Holdings) Company LimitedCGAHong Kong and China Gas Company LimitedDYA & CGAPing An Insurance (Group)Company of China, LtdCGAUnited Company RUSAL, international public joint-stock companyNon-listed Companies CategoriesExecutive DirectorsDYAMs Michelle ChanAS Watson IndustriesCGA Ir Prof Daniel M.ChengDunwell Technology (Holdings) Limited) (Dunwell Group)Ir Dr Cheng Sai Yau, VincentArup Fellow and Director of Climate and Sustainability in East AsiaDYAMr Orr Ka-yeung KevinWinner Medical (Hong Kong) LtdStatutory/ Non-profit-distributing Organisations CategoriesBoardsDYAHong Kong Tourism Board*In addition: recognition of Excellence in Board DiversityThe Institute of Internal Auditors Hong Kong*In addition: recognition of Excellence in Board DiversityThe guests of honour, special guests and officials to join the group photos together with the awardees (2nd row).About "HKIoD Award Series for Director Excellence"The HKIoD Award Series for Director Excellence is a project organised by The Hong Kong Institute of Directors ("HKIoD") and consists of two series of Awards.The first series, Directors Of The Year Awards, was inaugurated in 2001 as the first ever such Awards organised in Asia. As directors are ultimately responsible for corporate governance and leading the company in prosperity and integrity, the objectives of the Awards are to recognise outstanding boards and directors and to promote good practices in corporate governance and director professionalism. The Awards have become an annual project of impact in the community organised by HKIoD together with over 100 Project Partners. To date, 255 Awardees have been recognised for their achievements in demonstrating exemplary high standards in corporate governance and director practice.Inaugurated in 2024, Climate Governance Awards constitute the second series of HKIoD Awards with the objectives to recognise and inspire exemplary achievements in climate governance and to advocate climate action by directors. There are 10 awardees who have been acknowledged in the inaugural edition of the awards. It is critical time now for directors to address the risks and opportunities of climate change in board agendas and their governance role.Candidates are open to public nomination, with data processed in well-defined and stringent procedures, followed by interviews with independent consultants in utmost due diligence and finally selected by independent judges with high standards and fair judgment. Awards are presented by company categories, viz Listed Companies, Non-listed Companies and Statutory/Non-profit-distributing Organisations, and by capacities, viz Executive Directors, Non-Executive Directors and Boards.About The Hong Kong Institute of Directors ("HKIoD")The Hong Kong Institute of Directors ("HKIoD") is Hong Kong's premier body representing directors working together to advance corporate sustainability in creating long-term value for companies, their owners, stakeholders, humankind and Planet Earth through advocacy and standards-setting in corporate governance and director professionalism. Led by Founder Chairman Dr The Hon Moses Cheng, HKIoD was founded in 1997. Throughout the years, HKIoD is honoured to have the Chief Executive of HKSAR as the Institute's Patron. Membership of HKIoD comprises of directors from diverse industries and corporate types and includes Executive Directors, Non-Executive Directors and Independent Non-Executive Directors. With multi-culturalism and international perspectives, HKIoD organises activities that cover director training, seminars and forums, collective director voice, guideline establishment, public education, Award Series for Director Excellence, assessment of Corporate Governance Scorecard for listed companies etc.As a member body of the Global Network of Director Institutes ("GNDI"), HKIoD is committed to global collaboration in promoting good corporate governance and director professionalism. HKIoD is the appointed Host of the Hong Kong Chapter of Climate Governance Initiative, a global network that collaborates with the World Economic Forum in actively promoting directors' address of the risks and opportunities of climate change.For details please visit:http://www.hkiod.com|http://www.gndi.org|https://climate-governance.org/Media Enquiries:Award Series for Director Excellence:Strategic Public Relations Group LimitedThe Hong Kong Institute of DirectorsBrenda Chan+852 2114 4396/ brenda.chan@sprg.com.hkOdessa So +852 2889 4988/ odessa.so@hkiod.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Spritzer Clinches 10th Consecutive “Brand of the Year” Award at the World Branding Awards in London ACN Newswire

Spritzer Clinches 10th Consecutive “Brand of the Year” Award at the World Branding Awards in London

LONDON, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Spritzer has once again demonstrated its dominance in the bottled water industry by being named "Brand of the Year" in the national beverage division’s Water Category at the prestigious 2024–2025 World Branding Awards. The recognition marks Spritzer’s 10th consecutive win at the global awards, a testament to the brand’s enduring excellence in quality, branding, and consumer trust which further solidifies its position as Malaysia’s leading mineral water brand.Spritzer’s Head of Public Relations, Winnie Chin, accepting the Brand of the Year award under the national beverage division’s Water Category during the recent World Branding Awards at the Tower of LondonThe accolade was awarded by the World Branding Forum (WBF), a global non-profit organization devoted to advancing branding standards worldwide, at the annual World Branding Awards event which recognizes exceptional global and national brands across various categories. Winners in each category were evaluated through a rigorous process involving brand valuation, market research, and online public voting, showcasing a holistic assessment of brand strength and consumer trust. Most importantly, as the award evaluation relies heavily on consumer voting (70%), Spritzer’s continued wins over the years demonstrates the brand’s ability to consistently resonate with audiences and exceed customer expectations.Accepting the award on behalf of Spritzer during the awards ceremony held at the iconic Tower of London was Winnie Chin, Spritzer’s Head of Public Relations, who acknowledged the profound significance of this milestone: “We are honoured to receive this award for the 10th year running. Our achievements would not be possible without the unwavering support of our consumers, whose steadfast loyalty has made the Spritzer brand a household name. We also extend our gratitude to our partners for their collaboration and support and especially to our dedicated team for their hard work and creativity that have made this journey possible. We are deeply humbled and motivated to continue elevating our brand to greater heights, to build on Spritzer’s brand strength and commitment to excellence in all aspects of our company.”The award is a milestone that recognises Spritzer as a benchmark for consistency and adaptability to maintain brand trust and address emerging consumer needs in the ever-evolving market landscape. The company’s consistency, adaptability, and innovation have not only propelled it to the forefront of Malaysia’s bottled water industry but have also established it as a benchmark for quality, sustainability and innovation on a global stage. Spritzer’s decade-long winning streak at the awards exemplifies the brand’s commitment to producing high-quality natural bottled water and its reputation as a consumer-preferred brand.Building on this monumental achievement, Spritzer reaffirms its commitment to quality assurance as it continues to deliver bottled water with natural benefits and premium standards. The brand emphasises its dedication to sustainability goals and innovation as it continues to focus on advancing efforts to become a circular brand by 2030, aligned with global environmental initiatives, while leveraging cutting-edge technologies to introduce consumer-focused solutions to meet emerging needs.For more details about Spritzer, please visit our website at https://www.spritzer.com.my/.About Spritzer:Established in 1989, Spritzer Group has been a pioneer in providing Malaysians with natural mineral water sourced from a 440-acre green rainforest. Committed to innovation, Spritzer Group leads the Malaysian bottled water industry through manufacturing, distribution, marketing, and sales of its diverse product line. From renowned natural mineral water to refreshing non-carbonated fruit-flavoured drinks, each product is carefully crafted to meet consumer needs.Comprising eight business subsidiaries, Spritzer Group specializes in the production and distribution of silica-rich natural mineral water, sparkling natural mineral water, distilled drinking water, carbonated fruit-flavoured drinks, and non-carbonated fruit-flavoured drinks.With over 30 years of experience, Spritzer Group is Malaysia's largest and only listed bottled water producer. For more information, please visit www.spritzer.com.my. Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong ACN Newswire

Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong

SHANGHAI, Dec 2, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Government of the Hong Kong Special Administrative Region, China, has accepted Everest’s New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis. VELSIPITY(R) is an effective and convenient, once-daily, oral treatment for patients with moderately-to-severely active UC that has already been approved in the U.S. and E.U., and other countries, by Everest’s licensing partner, Pfizer. In Everest territories, the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China has approved the NDA for VELSIPITY(R) in April of this year and was implemented in the Guangdong-Hong Kong-Macau Greater Bay Area this October through the "Hong Kong and Macau Medicine and Equipment Connect" policy."Autoimmune disease is a core focus and a significant growth driver for our company. The number of UC patients in China is projected to double from 2019 to 2030 to approximately one million, highlighting the urgent need for novel treatments." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Previously, VELSIPITY(R) has already been approved in Macau, China, and was implemented in the Greater Bay Area through the connect policy. The company also plans to submit the NDA for approval by China’s National Medical Products Administration (NMPA) this year, with the aim of benefiting more Chinese patients as soon as possible."" This is an important advancement for etrasimod, bringing hope to patients in Hong Kong, China. This new-generation S1P receptor modulator is an oral, once-daily treatment that can provide patients with a chance for corticosteroid-free remission, mucosal healing, and rapid symptom relief, " said Prof. Wu Kaichun with the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial. “We hope China and other Asian countries can obtain approvals as soon as possible to benefit more patients."The acceptance of the NDA was based on results from the ELEVATE UC Phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that evaluated the safety and efficacy of etrasimod 2 mg once-daily on clinical remission in UC patients with moderately to severely active UC who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy. Nearly two-thirds of patients in ELEVATE UC 52 and ELEVATE UC 12 were naïve to biologic or JAK inhibitor therapy, and these studies were also the only studies for advanced therapies for ulcerative colitis to include patients with isolated proctitis. Both studies achieved all primary and key secondary efficacy endpoints, with a favorable safety profile consistent with previous studies of etrasimod.Everest conducted a multicenter, randomized, double-blind and placebo-controlled Phase 3 trial of etrasimod in Asian countries, including mainland China, China Taiwan and South Korea. This is the largest Phase 3 trial of moderately-to-severely active ulcerative colitis in Asia completed to date, with 340 eligible subjects randomized to treatment with etrasimod or placebo. The previously announced results of the induction period indicate that the clinical remission rate for patients treated with etrasimod 2mg was 25.0%, compared to 5.4% for those treated with placebo (difference 20.4%, p
More
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R)) ACN Newswire

雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德(VELSIPITY(R))

上海, 2024年12月2日 - (亞太商訊 via SeaPRwire.com) -雲頂新耀(HKEX 1952.HK)是一家專注于創新藥研發、臨床開發、製造和商業化的生物製藥公司,今日宣佈中國香港衛生署已正式受理伊曲莫德(VELSIPITY(R))用於治療中重度活動性潰瘍性結腸炎成人患者的新藥上市許可申請(NDA)。伊曲莫德是一款每日一次口服的一線先進療法,不僅使用方便、療效佳,而且具有良好的安全性特征。伊曲莫德已於去年10月和今年2月先後在美國和歐盟獲得新藥上市批准,同時,伊曲莫德也於今年4月獲得中國澳門特別行政區藥物監督管理局批准上市,並於今年10月通過「港澳藥械通」政策在粵港澳大灣區落地。雲頂新耀首席執行官羅永慶表示:「我們非常高興看到伊曲莫德的新藥上市許可申請在中國香港獲得正式受理。自身免疫性疾病是我們的重點關注領域和重要價值的潛在增長動力。到2030年,中國的潰瘍性結腸炎患者人數預計將達到約100萬人,超過2019年患者人數的一倍以上,存在迫切且巨大的未被滿足的臨床需求。伊曲莫德已在中國澳門獲批,並通過「港澳藥械通」政策率先在粵港澳大灣區落地。今年我們預計也將在中國大陸地區遞交伊曲莫德的新藥上市許可申請。期待伊曲莫德在更多地區獲批,進一步擴大可及性,造福廣大患者。」伊曲莫德亞太臨床試驗牽頭研究者、世界胃腸病學會執行理事、亞太消化學會副主席、中國人民解放軍空軍軍醫大學附屬西京醫院吳開春教授表示:「祝賀伊曲莫德取得的這一新進展,為中國香港的患者帶來了希望。伊曲莫德具有良好的獲益-風險特征,這種新一代S1P受體調節劑通過每日一次口服的治療方案,可快速起效,並達到無激素緩解、黏膜癒合,可為中重度活動性潰瘍性結腸炎成人患者提供先進的治療選擇。我們期待伊曲莫德在大中華區及其他亞洲國家早日獲批,為患者帶來福音。」伊曲莫德的申請是基於ELEVATE UC III期註冊研究(ELEVATE UC 52和ELEVATE UC 12)的結果,該研究旨在評價既往對至少一種常規治療、生物製劑或Janus激酶(JAK)抑制劑治療失敗或不耐受的中重度活動性潰瘍性結腸炎患者,每日一次服用2mg 伊曲莫德的安全性和療效。在ELEVATE UC 52和ELEVATE UC 12中,納入了一半以上嚴重活動性潰瘍性結腸炎患者(mMS≥7),並有近三分之一患者曾接受過生物製劑或JAK抑制劑治療。伊曲莫德的UC研究也是迄今唯一納入了孤立性直腸炎患者的UC研究。這兩項隨機、雙盲、安慰劑對照研究均達到了所有主要和關鍵次要終點,安全性特征與既往研究一致。在ELEVATE UC 52研究中,第12周時,接受伊曲莫德治療的患者臨床緩解率為27.0%(安慰劑組7.0%, 差異20.0%,P
More
Military Metals Completes Claim Staking Around the Last Chance Antimony-Gold Property in Nevada ACN Newswire

Military Metals Completes Claim Staking Around the Last Chance Antimony-Gold Property in Nevada

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - November 28, 2024) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report that it has completed additional staking of claims surrounding the Last Chance antimony-gold property, located in Nye County, Nevada, just over 70km north of the town of Tonapah and 12km due west of Kinross' Round Mountain gold mine. The Company recently entered into a letter of intent to acquire the Last Chance antimony-gold property. Please refer to the Company's news release dated November 14, 2024, for additional details about the Last Chance property.Scott Eldridge, Chief Executive Officer of the Company, commented, "Antimony prices have now risen to $38,000 USD per tonne, making antimony the top performing commodity thus far for 2024. China's export restriction that came into play September 15, 2024, has created a supply crunch that has magnified the need for domestic development of defense sector metals. This additional staking solidifies complete coverage of what we believe is the entire mineralized system surrounding the Last Chance antimony-gold property."Location map, Last Chance PropertyTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/231755_11f4bf32b4999b42_001full.jpgHistorical antimony-gold occurrences and a solitary shaft where limited historical production is recorded occur within a sequence of Paleozoic carbonates and Lower Mesozoic metamorphosed shales and carbonates; A series of ultramafic dykes as well as younger felsic intrusives and extrusives cut this sequence at several locations. Mineralization is structurally controlled, with folding, faulting and quartz veining seen throughout the metamorphosed sedimentary sequence at several locations across the property.A fence of claims was staked surrounding the Last Chance property to ensure that additional ground considered potentially prospective remains available to the Company when it begins its first field campaign scheduled for Q2/2025.The technical contents of this release were reviewed and approved by Avrom E. Howard, MSc, PGeo, geological consultant to Military Metals and a qualified person as defined by NI 43-101.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-Looking information in this news release includes statements related to the completion of a binding agreement and closing of the acquisition of the Last Chance Gold Property, as well as future plans for exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include meeting the conditions to close the acquisition of the Last Chance Gold Property, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both and any future activities in respect of the properties. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-Looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/231755 Copyright 2024 ACN Newswire via SeaPRwire.com.
More
GoKardz Launches Enterprise Module to Revolutionize Digital Business Card Management Empowering Businesses with Comprehensive Digital Networking Solutions ACN Newswire

GoKardz Launches Enterprise Module to Revolutionize Digital Business Card Management Empowering Businesses with Comprehensive Digital Networking Solutions

KUALA LUMPUR, Nov 26, 2024 - (ACN Newswire via SeaPRwire.com) - GoKardz, a trailblazing platform in digital business networking, proudly announces the launch of its Enterprise Module, an innovative solution designed to empower companies to create their company pages, onboard employees seamlessly, and maximize the potential of digital business cards. This addition merges traditional networking with advanced digital solutions to enhance connectivity and maintain brand identity, all while giving companies full control over their organizational presence.Enterprise Solutions for Modern BusinessesWith GoKardz’s Enterprise Module, companies can create customized company profiles and onboard employees effortlessly, equipping them with unique and customizable digital business cards that reinforce their brand identity. Employers gain full control over onboarding, ensuring a smooth, centralized process that guarantees all employees are equipped and up-to-date.Beyond individual digital business cards, businesses can now:Promote Products and Services: Increase brand exposure and engagement through GoKardz’s marketplace, showcasing offerings for maximum visibility.Advertise Open Positions: Post full-time, contractual, or freelance job opportunities, attracting top talent to meet business needs.Leverage Analytics: Gain actionable insights into visitor interactions, such as views of employee cards and clicks on links (e.g., website, email, phone), analytics that were previously impossible with traditional paper business cards.Reallocate Cards: Seamlessly transfer cards to new employees during transitions, maintaining continuity without any gaps in information.Seamless Digital ExperienceThe platform’s intuitive interface ensures companies can manage their digital assets and branding consistently across the organization. Employees can easily share their digital business cards through QR codes, NFC technology, Apple Wallets, and other methods, facilitating instant, scalable sharing while reducing environmental impact from traditional business cards.A Sustainable and Data-Driven Approach to NetworkingAs businesses increasingly turn to digital solutions, GoKardz leads the way in aligning technological innovation with environmental responsibility. By embracing digital business cards, companies not only improve their networking efficiency but also take a step towards sustainability. The analytics tools further support data-driven decision-making, empowering businesses to refine their outreach strategies based on real-time engagement metrics.A Word from Our LeadersAmaresh, Co-Founder of GoKardz, shared his vision:“At GoKardz, we’re committed to redefining professional networking with sustainable, data-driven solutions. Our enterprise tools help businesses modernize, reduce their environmental footprint, and optimize outreach strategies for greater impact.”Kuber Ventures, the venture studio that invested in GoKardz, emphasized:“Our investment in GoKardz stems from its ability to address a key gap in digital networking. The new Enterprise Module amplifies this vision by providing companies with innovative and efficient solutions that foster sustainable business growth.”With GoKardz, companies can confidently modernize their approach to networking, reduce their environmental impact, and gain valuable insights previously lost with traditional methods.GoKardz is available on iOS and Android, ready to transform the way professionals and businesses network and grow.For more information, visit www.gokardz.comMedia Contact: komal@mianext.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate ACN Newswire

Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed a Phase I clinical trial on its 2nd generation GKA candidate in U.S. at the 9th China BioMed Innovation and Investment Conference (CBIIC).The Phase Ia clinical trial of the second-generation GKA (HM-002-1005) was conducted in the United States in 40 subjects with Type 2 diabetes (T2D). This trial was randomized, double-blind, placebo-controlled, single-dose, focusing on safety, tolerability, and pharmacokinetics. The second-generation GKA is a novel molecular entity with optimized physicochemical properties, holding new patents, and serving as the prodrug of dorzagliatin (HMS5552). This study designed for once-daily oral administration. Its aim is to extend the drug's action duration in the body through sustained-release technology, enhance patient compliance, and prolong the stimulation of GLP-1 secretion in the intestines.The Single Ascending Dose (SAD) study demonstrates that HM-002-1005 tablets can be rapidly converted to HMS5552 in the human body, with minimal exposure level of prodrug in both blood and urine. The t1/2 (biological half-life) after a single dose of HM-002-1005 tablets was prolonged compared to dorzagliatin tablets. The Cmax of HMS5552 in plasma after a 184.5mg single dose is comparable to the plasma concentration of HMS5552 after a 75mg single dose of dorzagliatin tablet; likewise, the daily AUC of HMS5552 in plasma after a single dose of HM-002-1005 tablets is comparable to the exposure level of HMS5552 after a 75mg BID dose of dorzagliatin tablets. The research indicates that HM-002-1005 tablets are near-completely converted to HMS5552 in human, and its pharmacokinetic characteristics support for once-daily oral administration. The development of HM-002-1005 tablets not only contributes to enhancing patient medication adherence and effectively control blood glucose levels within 24 hours; meanwhile, it also offers the opportunity to explore the Maximum Tolerated Dose above 150mg daily to achieve better efficacy. The 75 mg BID dose regiment was developed under the concept of Minimum Therapeutic Effective Dose in Chinese T2D patients who suffered from an impairment of insulin secretion and significant reduction of early phase insulin. The different disease characters of T2D with obesity in western patient population would benefit dorzagliatin from its effects on GLP-1 secretion and improvement of insulin sensitivity.With the confirmation that the exposure level of HM-002-1005 tablets at 184.5mg is comparable to dorzagliatin tablets at 75mg (BID), we will further optimize the dosage form followed by a Multiple Ascending Dose (MAD) clinical development of the 2nd generation GKA in China and the United States.Dr. Li CHEN, founder and CEO of Hua Medicine, stated, “Hua Medicine has always been committed to treating Type 2 diabetes at its root cause by restoring patients’ ability to autonomously regulate blood glucose levels. Over the course of a decade, the Company has selected dosing and clinical research protocols that are safe and effective for the majority of Chinese diabetes patients, leading to the successful development of GKA and the clinical application of dorzagliatin. Building on this foundation, the Company will undergo a strategic upgrade by further exploring the therapeutic potential of GKA, enriching its product pipeline and seeking partners both domestically and internationally, in order to benefit a broader range of patients, expand into global markets, and effectively establish the brand identity of GKA medications while maximizing the commercial potential of our global first-in-class drugs.”About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC ACN Newswire

Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC

SHANGHAI, Nov 30, 2024 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx stock code: 2552) announced today that the Company has successfully completed its SENSITIZE study on the mechanism by which dorzagliatin improves the β-cell glucose sensitivity at the 9th China BioMed Innovation and Investment Conference (CBIIC).The SENSITIZE study was initiated by Professor Juliana Chan, an international endocrinology specialist at The Chinese University of Hong Kong, as the lead researcher. It is the first clinical study in Asian populations to evaluate the impact of GKA on β-cell glucose sensitivity in the populations with varying degrees of impaired glucose tolerance using the technology of hyperglycemic clamp. The study aims to explore the impairment of glucokinase (GK) function and clinical characteristics in different types of glucose dysregulation, providing new scientific evidence on the pathophysiology of Asian Type 2 diabetes and the central role of GK in blood glucose regulation.The SENSITIZE 2 study results announced at CBIIC demonstrate that a single dose of dorzagliatin restores GK enzyme activity, significantly improving the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT) in hyperglycemic clamp study. In addition, the SENSITIZE 1 study previously reported at the 2022 ADA annual meeting showed that dorzagliatin directly restores the activity of GK mutants, leading to significant improvements in the second-phase insulin secretion and β-cell glucose sensitivity in patients with glucokinase monogenic diabetes (GCK-MODY or MODY-2), and significantly enhance basal insulin secretion in newly diagnosed type 2 diabetes patients.Hua Medicine will continue to investigate β-cell glucose sensitivity improvement and incretin effect in response of repeated dose of dorzagliatin in individuals with intermediate hyperglycemia (IH) and Type 2 diabetes, in order to establish personalized intervention and treatment management plans for prediabetic and Type 2 diabetes patients.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (Dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.
More
華領醫藥宣佈成功完成在美國開展的第二代葡萄糖激酶激活劑I期臨床研究 ACN Newswire

華領醫藥宣佈成功完成在美國開展的第二代葡萄糖激酶激活劑I期臨床研究

香港, 2024年11月30日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥(「公司」,香港聯交所股份代號:2552.HK)今天在第九屆中國醫藥創新與投資大會(The China BioMed Innovation and Investment Conference,以下簡稱CBIIC)上宣佈,已經成功完成在美國開展的第二代葡萄糖激酶激活劑(GKA)的Ia臨床研究。第二代GKA(HM-002-1005)Ia臨床試驗是在美國40例2型糖尿病(T2D)受試者中進行的隨機、雙盲安慰劑對照、單劑量、安全性、耐受性、藥代動力學研究。第二代GKA是一種具有優化的理化性質的新分子實體,擁有新專利,為多格列艾汀(HMS5552)前藥。該項研究設計為每日一次口服給藥,旨在通過緩釋技術來延長藥物在體內的作用時間、改善患者依從性以及延長刺激腸道內GLP-1分泌的效果。這一單次劑量遞增(SAD)研究結果顯示,HM-002-1005片在人體內可迅速轉化為HMS5552,前藥在血漿和尿液中的暴露量極低。HM-002-1005片單次給藥後的t1/2(生物半衰期)相較於多格列艾汀片延長。184.5mg單次給藥後,血漿中HMS5552的Cmax與多格列艾汀片75mg單次給藥後的血漿HMS5552濃度相當;同時,血漿中HMS5552的單日AUC與多格列艾汀片75mg一天兩次給藥後HMS5552的暴露水平相當。該研究表明,HM-002-1005片在人體內幾乎完全轉化為HMS5552,且其藥代動力學特徵支持每日一次口服給藥方式。HM-002-1005片的開發不僅有利於提高患者服藥的依從性,實現24小時內有效控制血糖;同時,也為探索每日150mg以上的最大耐受劑量提供了機會,以獲得更好的治療效果。多格列艾汀75mg每日兩次(BID)劑量是根據最低有效治療劑量的治療理念,針對中國2型糖尿病患者普遍存在的胰島素分泌缺陷和早相胰島素分泌顯著降低而開發的劑型。西方2型糖尿病患者具有不同的疾病特點,往往合併肥胖症狀,多格列艾汀能夠促進GLP-1分泌、改善胰島素敏感性,有望為該患者群體帶來新的獲益。該研究結果確認HM-002-1005片184.5mg的暴露水平與多格列艾汀片75mg BID相當,公司將進一步優化劑型,在中國和美國進行第二代GKA的多次遞增劑量(MAD)臨床開發。華領醫藥創始人、CEO陳力博士表示:「華領醫藥始終致力於通過修復患者血糖自主調控能力,從源頭上治療2型糖尿病。公司歷經十年,選擇了針對大多數中國糖尿病患者安全有效的用藥劑量方案和臨床研究方案,實現了GKA的成功開發和多格列艾汀的臨床應用。在此基礎上,公司將進行戰略升級,通過繼續探索GKA的用藥潛力、豐富產品管線,在國內外尋求合作夥伴,惠及更多患者人群、拓展全球市場,更好地實現GKA藥物的品牌建設和全球首創新藥的商業價值。」關於華領華領醫藥(「本公司」)是一家總部位於中國上海的創新藥物研發和商業化公司,在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求,為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才,融合全球創新技術,依託全球優勢資源,研究開發突破性的技術和產品,引領全球糖尿病醫療創新。公司核心產品華堂寧(R)(多格列艾汀片)以葡萄糖傳感器葡萄糖激酶為靶點,提升2型糖尿病患者的葡萄糖敏感性,改善患者血糖穩態失調。2022年9月30日,華堂寧(R)已獲得中國國家藥品監督管理局(NMPA)的上市批准,用於單獨用藥或者與二甲雙胍聯合用藥,治療成人2型糖尿病。對於腎功能不全患者,無需調整劑量,是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址:www.huamedicine.com投資者電郵:ir@huamedicine.com媒體電郵:pr@huamedicine.com Copyright 2024 亞太商訊 via SeaPRwire.com.
More